K. Knopp

发表

Broad spectrum efficacy with LY2969822, an oral prodrug of metabotropic glutamate 2/3 receptor agonist LY2934747, in rodent pain models

E. Nisenbaum, Denise Morrow, Dominic L. Li, 2017, British journal of pharmacology.

The α2,3-selective potentiator of GABAA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats

P. Davis, W. Guo, F. Porreca, 2019, Pharmacology Biochemistry and Behavior.

Tetrodotoxin-Resistant Sodium Channels in Sensory Neurons Generate Slow Resurgent Currents That Are Enhanced by Inflammatory Mediators

E. Nisenbaum, T. Cummins, B. Priest, 2014, The Journal of Neuroscience.

Protein kinase C enhances human sodium channel hNav1.7 resurgent currents via a serine residue in the domain III–IV linker

E. Nisenbaum, T. Cummins, B. Priest, 2014, FEBS letters.

The Jak/STAT pathway: A focus on pain in rheumatoid arthritis.

P. Taylor, L. Simon, E. Choy, 2020, Seminars in arthritis and rheumatism.

Extracellular signal-regulated kinases mediate the enhancing effects of inflammatory mediators on resurgent currents in dorsal root ganglion neurons

E. Nisenbaum, T. Cummins, J. Mcdermott, 2019, Molecular pain.

Role of intraganglionic transmission in the trigeminovascular pathway

J. Hurley, P. E. Kunkler, K. Knopp, 2019, Molecular pain.

Pungency of TRPV1 agonists is directly correlated with kinetics of receptor activation and lipophilicity.

E. Sher, B. Liu, D. Ursu, 2010, European journal of pharmacology.

Synthesis and pharmacological characterization of C4-disubstituted analogs of 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: identification of a potent, selective metabotropic glutamate receptor agonist and determination of agonist-bound human mGlu2 and mGlu3 amino terminal domain struct

D. McKinzie, D. Clawson, S. Atwell, 2015, Journal of medicinal chemistry.

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

D. McKinzie, Xia Li, J. Witkin, 2014, Neuropharmacology.

Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial.

T. Le, J. Wernicke, S. Iyengar, 2006, Current therapeutic research, clinical and experimental.

Modulation of TARP γ8–Containing AMPA Receptors as a Novel Therapeutic Approach for Chronic Pain

D. Bredt, E. Nisenbaum, Y. Qian, 2019, The Journal of Pharmacology and Experimental Therapeutics.

An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis

Todd R. Wiernicki, Charles R. Yang, T. Suter, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Experimental design and reporting standards for improving the internal validity of pre-clinical studies in the field of pain: Consensus of the IMI-Europain consortium

Gillian L. Currie, R. Treede, M. Macleod, 2015, Scandinavian journal of pain.

TRPV3 in Drug Development

Dominic L. Li, L. Broad, K. Knopp, 2016, Pharmaceuticals.

Non-GABAergic Vestibular Nucleus Neurons Resurgent Na Currents in GABAergic and Similar Properties of Transient, Persistent, and

E. Nisenbaum, I. Raman, T. Cummins, 2015 .

Pharmacological interrogation of a rodent forced ambulation model: leveraging gait impairment as a measure of pain behavior pre-clinically.

K. Knopp, W. Guo, B. Adams, 2016, Osteoarthritis and cartilage.

A method to enhance the magnitude of tactile hypersensitivity following spinal nerve ligation in rats

R. Simmons, Beth M. Forster, K. Knopp, 2014, Journal of Neuroscience Methods.

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

D. McKinzie, Xia Li, J. Witkin, 2014, Neuropharmacology.